Items where authors include "O'Kane, M."

Article

Abani, O., Abbas, A., Abbas, F. et al. (7724 more authors) (2025) Sotrovimab versus usual care in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. The Lancet Infectious Diseases. ISSN 1473-3099

Abani, O., Abbas, A., Abbas, F. et al. (8041 more authors) (2025) Molnupiravir or nirmatrelvir–ritonavir plus usual care versus usual care alone in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. The Lancet Infectious Diseases. ISSN 1473-3099

Abani, O., Abbas, A., Abbas, F. et al. (8021 more authors) (2025) Higher dose corticosteroids in hospitalised COVID-19 patients requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial. eClinicalMedicine, 81. 103080. ISSN 2589-5370

Abani, O., Abbas, A., Abbas, F. et al. (8021 more authors) (2025) Higher dose corticosteroids in hospitalised COVID-19 patients requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial. EClinicalMedicine, 81. 103080. ISSN 2589-5370

Dark, P., Hossain, A., McAuley, D.F. et al. (543 more authors) (2025) Biomarker-guided antibiotic duration for hospitalized patients with suspected sepsis: the ADAPT-sepsis randomized clinical trial. Journal of the American Medical Association (JAMA), 333 (8). pp. 682-693. ISSN 0098-7484

Faust, S.N., Haynes, R., Jones, C.E. et al. (7370 more authors) (2024) Immunomodulatory therapy in children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS, MIS-C; RECOVERY): a randomised, controlled, open-label, platform trial. The Lancet Child & Adolescent Health, 8 (3). pp. 190-200. ISSN 2352-4642

Faust, S.N., Haynes, R., Jones, C.E. et al. (7370 more authors) (2024) Immunomodulatory therapy in children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS, MIS-C; RECOVERY): a randomised, controlled, open-label, platform trial. The Lancet Child & Adolescent Health, 8 (3). pp. 190-200. ISSN 2352-4642

Abani, O., Abbas, A., Abbas, F. et al. (7989 more authors) (2023) Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. The Lancet Diabetes & Endocrinology, 11 (12). pp. 905-914. ISSN 2213-8587

Brown, A., Flint, S.W. orcid.org/0000-0003-4878-3019, Dicken, S.J. et al. (5 more authors) (2023) The impact of living through COVID‐19 pandemic on mental health, food insecurity, loneliness and health behaviours in people with obesity. Journal of Human Nutrition and Dietetics, 36 (3). pp. 1011-1018. ISSN 0952-3871

Abani, O., Abbas, A., Abbas, F. et al. (8104 more authors) (2023) Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial. The Lancet, 401 (10387). pp. 1499-1507. ISSN 0140-6736

Sydes, M.R., Barbachano, Y., Bowman, L. et al. (25 more authors) (2021) Realising the full potential of data-enabled trials in the UK : a call for action. BMJ Open, 11 (6). e043906. ISSN 2044-6055

Brown, A., Flint, S.W. orcid.org/0000-0003-4878-3019, Kalea, A.Z. et al. (3 more authors) (2021) Negative impact of the first COVID-19 lockdown upon health-related behaviours and psychological wellbeing in people living with severe and complex obesity in the UK. EClinicalMedicine, 34. 100796. ISSN 2589-5370